Welcome to the international HTA database

Showing [24312 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lazertinib (NSCLC, first line, in combination with amivantamab) – Benefit assessment according to §35a Social Code Book V]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Exagamglogene autotemcel (sickle cell disease) – Assessment according to §35a (para. 1, sentence 11) Social Code]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Exagamglogene autotemcel (transfusion dependent beta thalassaemia) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[AR101 (peanut allergy, 1 to 3 years) – Benefit assessment according to §35a Social Code Book V]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Osimertinib (locally advanced, unresectable NSCLC) – Benefit assessment according to §35a Social Code Book V]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[CRP apheresis in acute anterior myocardial infarction Addendum to project E22-11]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Phonocardiography to rule out coronary heart disease (Addendum to Project E19-09)]
2025	Andalusian Health Technology Assessment Area (AETSA)	[Impact of multidisciplinary hospital teams employing ultrasound-guided vascular access]
2025	NIHR Health Services and Delivery Research programme	Co-designing and testing the learn together guidance to support patient and family involvement in patient safety investigations: a mixed-methods study
2025	NIHR Health Technology Assessment programme	Behaviour change interventions to promote physical activity in people with intermittent claudication: the OPTIMA systematic review
2025	NIHR Health Technology Assessment programme	Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation
2025	NIHR Health Technology Assessment programme	Sputum colour charts to guide antibiotic self-treatment of acute exacerbation of chronic obstructive pulmonary disease: the Colour-COPD RCT
2025	NIHR Health Services and Delivery Research programme	Implementing routine assessment of perinatal anxiety: case studies
2025	NIHR Health Services and Delivery Research programme	How to implement digital clinical consultations in UK maternity care: the ARM@DA Realist Review
2025	Health Information and Quality Authority (HIQA)	Evidence review of specialist cardiac services
2025	Agency for Care Effectiveness (ACE)	Deucravacitinib for moderate-to-severe chronic plaque psoriasis
2025	Agency for Care Effectiveness (ACE)	Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma
2025	Agency for Care Effectiveness (ACE)	Glofitamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2025	Agency for Care Effectiveness (ACE)	Pembrolizumab for treating locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma
2025	Agency for Care Effectiveness (ACE)	Pembrolizumab for treating resectable Stage II, IIIA, or IIIB (T3-4N2) non-small-cell lung cancer
2025	Agency for Care Effectiveness (ACE)	Sacituzumab govitecan for unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer
2025	Agency for Care Effectiveness (ACE)	Triple therapy inhalers for treating asthma or chronic obstructive pulmonary disease
2025	Agency for Care Effectiveness (ACE)	Pneumococcal conjugate vaccines (15-valent and 20-valent) for the prevention of pneumococcal disease in adults
2025	NIHR Health Technology Assessment programme	Bisoprolol for patients with chronic obstructive pulmonary disease at high risk of exacerbation: the BICS RCT
2025	NIHR Health Technology Assessment programme	Effectiveness of biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: the BATCH RCT
2025	NIHR Health Technology Assessment programme	Establishing the best step-up treatments for children with uncontrolled asthma despite inhaled corticosteroids: the EINSTEIN systematic review, network meta-analysis and cost-effectiveness analysis using individual participant data
2025	NIHR Health Technology Assessment programme	Software with artificial intelligence-derived algorithms for detecting and analysing lung nodules in CT scans: systematic review and economic evaluation
2025	NIHR Health Technology Assessment programme	Rapid tests to inform triage and antibiotic prescribing decisions for adults presenting with suspected acute respiratory infection: a rapid evidence synthesis of clinical effectiveness and cost–utility studies
2025	Center for Outcomes Research and Economic Evaluation for Health (C2H)	Cost-effectiveness evaluation of epcoritamab for relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments
2025	National Institute for Health and Care Excellence (NICE)	Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B. NICE highly specialised technologies guidance 32
2025	National Institute for Health and Care Excellence (NICE)	Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over. NICE highly specialised technologies guidance 33
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Algorithm for the management of low back pain with or without radicular pain]
2025	Agency for Care Effectiveness (ACE)	Elastomeric infusion pumps for outpatient parenteral antimicrobial therapy
2025	Agency for Care Effectiveness (ACE)	Deep brain stimulators for treatment of Parkinson disease, dystonia or essential tremor
2025	Agency for Care Effectiveness (ACE)	Antibacterial envelope for implantable neurostimulator infection control
2025	NIHR Health Technology Assessment programme	Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial
2025	NIHR Health Technology Assessment programme	Technology-enabled CONTACT tracing in care homes in the COVID-19 pandemic: the CONTACT non-randomised mixed-methods feasibility study
2025	NIHR Health Technology Assessment programme	Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and economic analysis
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Non-pharmacological interventions, other than psychosocial ones, for youth aged under 18 with attention deficit/hyperactivity disorder (ADHD)]
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Pharmacological treatment of migraine]
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Relevance of adding vitamin-dependent rickets screening to neonatal screening]
2025	Technology Assessment at SickKids (TASK)	A microcosting and cost consequence analysis from a randomized controlled trial comparing genome sequencing to exome sequencing for genetic diagnosis
2025	Agency for Care Effectiveness (ACE)	EchoGo Heart Failure to aid in the diagnosis of heart failure with preserved ejection fraction
2025	Agency for Care Effectiveness (ACE)	Fibresolve to aid in the diagnosis of idiopathic pulmonary fibrosis
2025	NIHR Health Technology Assessment programme	High-flow nasal cannula therapy versus continuous positive airway pressure for non-invasive respiratory support in paediatric critical care: the FIRST-ABC RCTs
2025	National Institute for Health and Care Excellence (NICE)	Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour. NICE interventional procedures guidance 800
2025	National Institute for Health and Care Excellence (NICE)	Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal). NICE technology appraisal guidance 1052
2025	National Institute for Health and Care Excellence (NICE)	Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over. NICE technology appraisal guidance 1051
2025	National Institute for Health and Care Excellence (NICE)	Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over. NICE technology appraisal guidance 1054
2025	National Institute for Health and Care Excellence (NICE)	Cladribine for treating active relapsing forms of multiple sclerosis. NICE technology appraisal guidance 1053
2025	National Institute for Health and Care Excellence (NICE)	Relugolix–estradiol–norethisterone for treating symptoms of endometriosis. NICE technology appraisal guidance 1057
2025	National Institute for Health and Care Excellence (NICE)	Molnupiravir for treating COVID-19. NICE technology appraisal guidance 1056
2025	National Institute for Health and Care Excellence (NICE)	Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 1055
2025	National Institute for Health and Care Excellence (NICE)	Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 1058
2025	NIHR Health and Social Care Delivery Program	Opportunities and practices supporting responsive health care for forced migrants: lessons from transnational practice and a mixed-methods systematic review
2025	NIHR Health and Social Care Delivery Program	Approaches used to prevent and reduce the use of restrictive practices on adults with learning disabilities: a realist review
2025	NIHR Health Technology Assessment programme	A network approach to addressing the needs of patients with incurable head and neck cancer and their families
2025	NIHR Health and Social Care Delivery Program	The effectiveness and cost-effectiveness of the NHS Diabetes Prevention Programme (NHS-DPP): the DIPLOMA long-term multimethod assessment
2025	Penn Medicine Center for Evidence-based Practice (CEP)	Alpha-blocking medication before removal of indwelling urinary catheters
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Hospital at home in Québec healthcare institutions: considerations to support program implementation]
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[New drug treatments for Alzheimer's disease: considerations for patient management]
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Treatment of mitral insufficiency with a percutaneous device with clip (TEER) in Quebec - characteristics, continuum of care and clinical outcomes of adult clientele treated between 2019-2020 and 2021-2022]
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Tumor biomarkers related to the management of bladder cancer patients]
2025	NIHR Health and Social Care Delivery Program	Optimising neonatal services for very preterm births between 27+0 and 31+6 weeks gestation in England: the OPTI-PREM mixed-methods study
2025	NIHR Health and Social Care Delivery Program	Organising general practice for care homes: a multi-method study
2025	HTA South	[Ultraviolet light disinfection of flexible endoscopes without working channels: a systematic review and assessment of medical, economical, and organisational aspects]
2025	NIHR Health and Social Care Delivery Program	Exploring voluntary sector specialist services for victim-survivors of sexual violence in England: the PROSPER co-production study
2025	NIHR Health and Social Care Delivery Program	Direct oral penicillin challenge in secondary care with low-risk patients: the SPACE mixed-methods study with cost-effectiveness analysis
2025	NIHR Health Technology Assessment programme	Evaluation of prognostic models to improve prediction of metastasis in patients following potentially curative treatment for primary colorectal cancer: the PROSPECT trial
2025	NIHR Health Technology Assessment programme	Supporting self-management with an internet intervention for low back pain in primary care: a RCT (SupportBack 2)
2025	NIHR Health and Social Care Delivery Program	Formulating outputs from a mixed-methods study of access to general practice: a series of collaborative stakeholder workshops
2025	NIHR Health Technology Assessment programme	Lessons from the PROTECT-CH COVID-19 platform trial in care homes
2025	NIHR Health Technology Assessment programme	Stopping anticoagulation for isolated or incidental subsegmental pulmonary embolism: the challenges and lessons from the STOPAPE RCT
2025	Institut national d'excellence en sante et en services sociaux (INESSS)	[Fibrin sealants and hemostatic matrices in an intraoperative context]
2025	NIHR Health Technology Assessment programme	Anti-VEGF drugs compared with laser photocoagulation for the treatment of proliferative diabetic retinopathy: a systematic review and individual participant data meta-analysis
2025	NIHR Health Technology Assessment programme	A personalised health intervention to maintain independence in older people with mild frailty: a process evaluation within the HomeHealth RCT
2025	NIHR Health Services and Delivery Research programme	Multiple Symptoms Study 3 – an extended-role general practitioner clinic for patients with persistent physical symptoms: a randomised controlled trial
2025	NIHR Health Services and Delivery Research programme	The impact of redeployment during COVID-19 on nurse well-being, performance and retention: a mixed-methods study (REDEPLOY)
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Arthrofibrosis (excessive scarring) in the knee: can surgical procedures reduce movement restrictions and pain?]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Hip osteoarthritis: can physiotherapy delay or avoid surgery?]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Capivasertib (breast cancer) – 2nd addendum to Project A24-105]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bulevirtide (chronic hepatitis D, children >= 3 to < 18 years, >= 10 kg) – assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Eliglustat (Gaucher disease type 1; children and adolescents) – assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Mirvetuximab soravtansin (ovarian cancer) – assessment in accordance with §35a (1) Sentence 11 Social Code Book (SGB) V]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Delgocitinib (moderate to severe chronic hand eczema) – addendum to Project A24-107]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Capivasertib (breast cancer) – addendum to Project A24-105]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Atezolizumab (NSCLC, first line) – addendum to Project A24-97]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (urothelial cancer, first line treatment, combination with enfortumab vedotin) – addendum to Project A24-99]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Enfortumab vedotin (urothelial cancer, first line treatment, combination with pembrolizumab) – addendum to Project A24-98]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sotatercept (pulmonary arterial hypertension) – addendum to Project A24-96]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Crovalimab (paroxysmal nocturnal haemoglobinuria) – addendum to Project A24-94]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Insulin icodec (type 1 diabetes mellitus) – addendum to Project A24-90]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Erdafitinib (urothelial carcinoma) – benefit assessment according to §35a Social Code Book V]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tislelizumab (gastric or gastroesophageal junction adenocarcinoma, HER2-negative) – benefit assessment according to §35a Social Code Book V]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tislelizumab (oesophageal squamous cell carcinoma, second line) – benefit assessment according to § 35a Social Code Book (SGB) V]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tislelizumab (NSCLC, second line) - benefit assessment according to § 35a Social Code Book (SGB) V]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tislelizumab (non-squamous NSCLC) - benefit assessment according to §35a Social Code Book (SGB) V]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tislelizumab (squamous NSCLC, first line) – benefit assessment according to §35a Social Code Book (SGB) V]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ribociclib (breast cancer, adjuvant treatment) – benefit assessment according to §35a Social Code Book V]
2025	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Linzagolix (endometriosis) – Benefit assessment according to §35a Social Code Book V]